Genmab — Maj 2015
-
Ok..
-
Det kunne du jo bringe på bane over for Jan på Q&A.
-
Det plejer du jo.
-
Jeg er desværre forhindret i at være moderator denne gang, så i må bære over med gammelfar
-
Du er nu så sød 89.
-
"Genmab: Fokus på meldinger om udviklingen i pipelinen i kvartalsregnskabet"http://www.proinvestor.com/analyser
-
-
06:52
Genmabs kræftmiddel Arzerra har fået en positiv anbefaling af de skotske sundhedsmyndigheder. Det fremgår af Pharma Times.Skotterne anbefaler begrænset brug af Arzerra som førstegangsbehandling af patienter med kronisk lymfatisk leukæmi, som ikke kan modtage Fludarabine-baseret behandling.
-
-
Danmarks bedste biotekanalytiker har nu også øget Exiqons kursmål til 14 DKK: http://www.jyskebank.dk/finansnyt/aktieanbefalinger/aktiedetaljer?cat=JyskeMarkets/EXQ.CO&assetid=EXQ.CO
-
Mon det er et salgssignal?
-
Var det i dag programmet for J&J R&D dagen kom ud ?
-
The agenda for the day will be posted on the Investor Relations website on approximately May 13th.
Investors and other interested parties may access this meeting by visiting the Company's website at www.investor.jnj.com for a simultaneous webcast of the presentations.
-
Så i morgen kommer "agendaen"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind